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Abstract
Background: The high mobility group A1 proteins (HMGA1a/HMGA1b) are highly conserved
between mammalian species and widely described as participating in various cellular processes. By
inducing DNA conformation changes the HMGA1 proteins indirectly influence the binding of
various transcription factors and therefore effect the transcription regulation. In humans
chromosomal aberrations affecting the HMGA1 gene locus on HSA 6p21 were described to be the
cause for various benign mesenchymal tumours while high titres of HMGA1 proteins were shown
to be associated with the neoplastic potential of various types of cancer. Interestingly, the absence
of HMGA1 proteins was shown to cause insulin resistance and diabetes in humans and mice.
Due to the various similarities in biology and presentation of human and canine cancers the dog
has joined the common rodent animal model for therapeutic and preclinical studies. Accordingly,
the canine genome was sequenced completely twice but unfortunately this could not solve the
structure of canine HMGA1 gene.
Results: Herein we report the characterisation of the genomic structure of the canine HMGA1
gene consisting of 7 exons and 6 introns spanning in total 9524 bp, the in vivo localisation of the
HMGA1 protein to the nucleus, and a chromosomal assignment of the gene by FISH to CFA12q11.
Additionally, we evaluated a described canine HMGA1 exon 6 SNP in 55 Dachshunds.
Conclusion: The performed characterisations will make comparative analyses of aberrations
affecting the human and canine gene and proteins possible, thereby providing a basis for revealing
mechanisms involved in HMGA1 related pathogenesis in both species.
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Background
The high mobility group A (HMGA) proteins are small
chromatin associated non-histone proteins named
according to their characteristic motility in acid-urea poly-
acrylamide gel electrophoresis. The protein family con-
sists of the three proteins HMGA1a, HMGA1b and
HMGA2 which are encoded for by two different genes
(HMGA1 and HMGA2). The functional motifs of these
proteins, named AT-hooks, bind to the minor groove of
DNA causing conformational changes of the DNA mole-
cule. On genomic level these structural changes influence
the binding of various transcription factors and thus indi-
rectly influence the transcription regulation, which classi-
fies the HMGA proteins as so called architectural
transcription factors (for detail see [1]).
In previous studies we characterised the canine HMGA1
cDNAs and proteins and in comparative analyses of these
molecules showed that they are highly conserved between
different mammalian species. The observed number of
amino acid changes seen across mammalian species (cat-
tle, dog, hamster, horse, mouse, pig, and rat) vary between
0 to 3 when compared to the human molecules [2-10].
Interestingly, only the canine HMGA1 proteins are 100%
identical to their respective human counterparts [11].
The HMGA1 proteins are well known to play a significant
role in the pathogenesis of various diseases including can-
cer. In humans, chromosomal aberrations affecting the
HMGA1 gene locus on HSA 6p21 were described for vari-
ous benign mesenchymal tumours, e.g. endometrial pol-
yps, lipomas, pulmonary chondroid hamartomas, and
uterine leiomyomas [12-14]. The observed aberrations are
supposed to lead to an up-regulation of the HMGA1 gene
in the affected tumours, as opposed to adult healthy tis-
sues where HMGA gene expression is low or hardly meas-
urable [9,15,16]. In malignant neoplasias HMGA1
expression is reported to be associated with an aggressive
behaviour of tumours. Accordingly, HMGA1 overexpres-
sion was detected in various malignancies including thy-
roid, lung, prostatic, pancreatic, uterine cervical, and
colorectal carcinoma [17-22]. Thus HMGA expression is
supposed to present a powerful diagnostic and prognostic
molecular marker due to the described correlation
between HMGA expression and tumour aggressiveness.
Whilst overexpression of HMGA1  is clearly associated
with cancerogenesis the disruption of the HMGA1 gene
and thus induced loss of HMGA1 expression shows signif-
icant pathogenic effects. Heterozygous and homozygous
Hmga1 knock-out mice develop cardiac hypertrophy
combined with hematologic malignancies e.g. B cell lym-
phoma and myeloid granuloerythroblastic leukemia [23].
Additional research with Hmga1 knock-out mice targeting
diabetes presented by Foti et al. (2005) showed that loss
of Hmga1 expression is clearly associated with signifi-
cantly decreased insulin receptor expression and thus
causes a characteristic diabetes type 2 phenotype in mice
[24].
The various similarities in presentation and biology of
numerous canine and human diseases including cancer
suggest similar mechanisms to be involved in the respec-
tive pathogenic events. Accordingly, at least a dozen dis-
tinct canine cancers are hypothesized to be appropriate
models for their human counterparts, among those oste-
osarcoma, breast carcinoma, oral melanomas, lung carci-
nomas and malignant non-Hodgkin's lymphomas [25].
The characterization of disease related genes and their
protein biology will allow for comparative studies to
reveal the molecular mechanisms involved therein and
serve as a basis for future clinical studies.
Results and discussion
The  HMGA1  gene and its proteins HMGA1a and
HMGA1b are described as regulating multiple cellular
processes and are widely reported to be associated with
various diseases including diabetes and cancer. In previ-
ous studies we characterised the canine HMGA1 cDNAs
and proteins completely and did comparative analyses of
these molecules to the respective counterparts of different
species and showed high evolutionary conservation. The
fact that several canine and human cancer types show
striking similarities in presentation and biological behav-
iour, e.g. spontaneous occurrence and metastasis patterns,
strongly suggests similar mechanisms to be involved in
the respective pathogenic events of both species. Thus,
various canine tumours are currently used as models for
several human cancer types. Accordingly, comprehension
of the canine gene and its gene products is precondition
for comparative analyses, allowing the revelation of
molecular effects involved in these pathogenic presenta-
tions. Understanding and comparison of the respective
genes will thus benefit both species. The exact mechanism
for the emergence of the pathogenic effects caused by
chromosomal aberrations affecting the human HMGA1
gene in benign mesenchymal tumours, e.g. endometrial
polyps, lipomas, pulmonary chondroid hamartomas, and
uterine leiomyomas [12-14] are not completely under-
stood. However, it is currently supposed that the aberra-
tion causes up-regulation of the HMGA1  gene in the
affected neoplasias. The principal aim of the study was to
characterize the genomic structure of the canine HMGA1
gene allowing the comparison of its genomic structure to
the counterparts of other mammals and thus allowing a
further evaluation of evolutionary conservation of the
gene and a comparative analysis of chromosomal aberra-
tions in both species. Additional aims were the in vivo
localization of the canine HMGA1 protein and the evalu-BMC Genetics 2008, 9:49 http://www.biomedcentral.com/1471-2156/9/49
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ation of a previously described point mutation which
causes a disrupted protein.
Genomic structure, BAC Screening and FISH
A canine HMGA1 genomic PCR reaction was established
and used for screening of a canine BAC for identification
of the canine HMGA1 gene locus by FISH. The verified
BAC 572 P20 K12 RC was used for FISH experiments. Ten
well spread metaphases were analysed and showed signals
on both chromatides of both chromosomes CFA 12q11
(Figure 1). The chromosomal localisation was done fol-
lowing the nomenclature established by Reimann et al.
[26]. Existing painting probe based synteny studies and
RH analyses [27] indicated that the canine CFA 12 shares
homology with the human chromosome 6 on which the
HMGA1 gene is located at HSA 6p21. Chromosomal aber-
rations affecting CFA 12 are not or barely reported to be
significantly associated with canine neoplasias [28,29].
While previous studies reported the localization of a
HMGA1 gene positive BAC to CFA 23 [30], the performed
in silico analyses and the recently published canine
genome assembly [31] support the herein described
assignment of the canine HMGA1 gene to CFA 12q11 by
FISH described in this study. Comparative chromosomal
in silico analyses using the "Evolutionary Highway" http:/
/evolutionhighway.ncsa.uiuc.edu/results.html showed
similar results.
The genomic structure of the canine HMGA1 gene consists
in total of the 7 exons and 6 introns. Overall the canine
HMGA1 gene spans 9524 bp. The exon/intron structure,
size and the homologies to their human counterparts
were analysed and defined (Figure 2, Table 1). The total
identity to the corresponding human region is 62.8%. In
detail, the identities of the exons vary between 74.6% and
97.8% to their human counterpart, while the introns
show identities between 58.9% and 92.4% (for details see
Table 1). The newly characterized sequences combined
with the analyses performed in silico revealed that the
exon 4, which exists in humans, is missing on genomic
level in the canine genome. This exon 4 deletion also
exists in the mouse genome and affects the respective
mRNAs of both species in their 5' UTR. As the genomic
characterization of the canine HMGA1 gene was not avail-
able when the exons were named previously, the number-
ing at that time was based on the respective human exon
numbers as defined by Friedmann et al. [32]. Conse-
quently, as it is now known that the canine genomic
sequence is lacking an equivalent to human exon 4, the
previously used canine exon numbering should be revised
with the then named canine exon 5 now being canine
exon 4 and so on (Figure 2, Table 1). However, a part of
intron 2 remains unsequenced due to an extensive CG
repeat which also exists in the human counterpart
(90%CG), and only the number of nucleotides (311 bp)
could be identified. The genomic sequences were submit-
FISH-Mapping of the canine HMGA1 Figure 1
FISH-Mapping of the canine HMGA1. Canine metaphase spread after GTG-banding (left) and the same metaphase after 
fluorescence in situ hybridisation with BAC MGA 572 P20 K12 RC showing signals on both chromosomes 12 (right).BMC Genetics 2008, 9:49 http://www.biomedcentral.com/1471-2156/9/49
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ted to the NCBI database (bankit1078465,
bankit1078536, bankit1078968).
Exon 6 SNP evaluation
While characterising the canine HMGA1 gene we screened
twelve different canine breeds for point mutations affect-
Genomic structure of the canine HMGA1 gene Figure 2
Genomic structure of the canine HMGA1 gene. Detailed structure of the genomic organisation of the canine HMGA1 
gene.
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Table 1: Detailed analysis of the canine HMGA1 gene genomic elements
Element of canine HMGA1 gene Size in bp Identity to human counterpart in % (GenBank NC_000006))
Total gene 9524 62.8
Detail exons/introns (revised numbering)*
Exon 1 94 97.8
Intron 1 196 92.4
Exon 2 164 95.8
Intron 2 311 -
Exon 3 162 74.6
Intron 3 3096 58.9
Exon 4 (5) 179 93.9
Intron 4 (5) 1761 51.1
Exon 5 (6) 84 96.4
Intron 5 (6) 584 57.5
Exon 6 (7) 51 94.1
Intron 6 (7) 1459 58.1
Exon 7 (8) 1386 75.4
Identity comparison of the genomic elements of the canine HMGA1 gene with its respective human counterparts.BMC Genetics 2008, 9:49 http://www.biomedcentral.com/1471-2156/9/49
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ing the protein coding region. A Dachshund sample
showed a transition from A to G in exon 6 (according to
revised exon numeration) leading to an amino acid
exchange from threonine to alanine causing a mutated
HMGA1 protein [9]. To elucidate if the observed exchange
is frequently existent in the Dachshund population we
screened 55 Dachshunds for the respective mutation (Fig-
ure 3). The results obtained by sequencing and restriction
fragment analysis clearly showed that the previously
found mutation is a rare event, as none of the screened 55
Dachshunds showed the mutation. Thus our findings sug-
gest that the previously found aberrant HMGA1  allele
leading to a mutated protein form is unlikely to play a
major role in HMGA1 pathogenesis in Dachshunds.
In general, different species show significant differences
considering the number and probability of described
SNPs. This fact surely is directly dependent on total num-
bers of studies and sequencing reactions performed for
the different species. While in 2001 Sachidanandam et al.
[33] detected 1.42 million SNPs in the human genome
with one SNP per 1.9 kb the currently estimated total
number reported SNPs in the public databases is approx.
9 million for the human genome [34]. For the dog Lind-
blad-Toh et al. reported 2.5 million SNPs, whereas the
probability differs depending on the breed between one
SNP per 1500 bp and 900 bp [31]. Comparable to the
human genome the total numbers of reported SNPs in the
other different species is expected to increase significantly
according to the performed research efforts, leading to
increased knowledge of effects caused by SNPs in general.
HMGA1 in vivo localization
The in vivo localization of the canine HMGA1 proteins via
expression of a canine HMGA1a-GFP fusion protein
showed that equivalently to its human counterpart the
protein is located in the nucleus (Figure 4). Proteins of the
HMGA family are described to be architectural transcrip-
tion factors, and thus a localisation in the nucleus seems
obvious. However, further localisation and function of
these proteins seem to be very likely, due to the fact that
application of recombinant HMGA1 proteins to porcine
cartilage cells in vitro showed significant increase of cell
proliferation (Richter et al. accepted for publication). For
a further member of the HMG proteins called HMGB1 the
existence of an extracelluar function was recognised only
a long time after its initial characterisation as an architec-
tural transcription factor, revealing a direct influence of
Position of the evaluated Dachshund point mutation Figure 3
Position of the evaluated Dachshund point mutation. Strategic position of the evaluated point mutation screened in 55 
Dachshunds.
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C
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extracellular HMGB1 on metastatic events [35-37]. Thus,
we suppose that a similar mechanism could also exist for
HMGA proteins and are currently working towards its
identification.
Conclusion
Knowledge about the structure of genes and proteins is
precondition to use them as potential therapeutic targets,
markers or for revealing mechanisms involved in relevant
pathogenic events. The canine and human HMGA genes
and proteins have widely been shown to be involved in
various diseases especially in cancer. Due to the numerous
reasons for using the dog as a model system for human
cancer research the characterisation of canine genes and
proteins is of special interest. The performed characterisa-
tions of the canine HMGA1 gene and proteins will allow
performing comparative analyses of aberrations affecting
the human and canine genes and proteins as basis for
revealing mechanisms involved in HMGA1 related patho-
genesis in both species.
Methods
BAC library screening
A PCR reaction for the use in PCR-based screening of the
Canis familiaris DogBAC library (Schelling et al., 2002)
(Institute of Animal Genetics, Nutrition and Housing,
University of Berne, Berne, Switzerland) for a BAC clone
containing HMGA1 was established using canine genomic
DNA derived from blood. The primers A1In5up (5'
GGCATCCGGTGAGCAGTG 3') and A1In6lo (5' CAG-
GCAGAGCACGCAGGAC 3') were designed using
GeneBank sequences AY366395 &NW_876254. PCR
parameters were: 95°C for 5 min, followed by 30 cycles of
95°C 30 sec, 59.3°C 30 sec, 72°C 30 sec, and a final elon-
gation of 72°C for 10 min. The corresponding 201 bp
PCR product was cloned into the pGEM-T Easy vector sys-
tem (Promega, Mannheim, Germany) and verified by
sequencing. The DNA contigs and alignments were done
with Lasergene software (DNAstar, Madison, USA) and
various sequences from the NCBI database (AY366395,
NW_876254). The verified BAC clone MGA 572 P20 K12
RC was used as probe for the following FISH experiments.
Slide Preparation
1 ml of canine whole blood was incubated for 72 h in
Chromosome Medium B (Biochrom, Berlin, Germany).
Subsequently, colcemide (0.1 μg/ml) (Biochrom, Berlin,
Germany) was added for 2 hours. The cells were centri-
fuged at 135 × g for 10 min and incubated for 20 min in
0.05 M KCl. Finally the cells were fixed with methanol/
glacial acetic acid. This suspension was dropped on ice-
cold slides and dried for at least 7 days at 37°C. The chro-
mosomes were stained by GTG banding for karyotype
description. Prior to use in FISH investigations, the slides
were destained with 70% ethanol.
Fluorescence in situ Hybridization
MGA 572 P20 K12 RC BAC-DNA was digoxigenin
labelled (Dig-Nick-Translation-Kit, Roche, Mannheim,
Germany). The hybridization mixture contained 200 ng
probe, 40 ng ssDNA, 600 ng sonicated dog DNA, 2 × SSC,
2 × SSPE, 50% formamide and 10% dextran sulfate. 50 μl
of this mixture were applied to each slide and the cover
slips were sealed with rubber cement. Probe and chromo-
somes were denatured at 75°C on an Eppendorf Thermo-
cycler gradient, using the in situ adapter. Afterwards, the
slides were incubated in a moist chamber at 37°C over
night. Cover slips were carefully removed and the slides
were incubated in 0.1 × SSC at 61°C and 1 × PBS at RT.
Slides were then covered with 100 μl non fat dry milk
(NFDM) for 20 min. at 37°C in a moist chamber. For sig-
nal detection 100 μl NFDM containing 3 μg of Anti-Dig-
oxigenin-Rhodamine, Fab fragments (Roche, Mannheim,
Germany), were added to each slide and again incubated
for 20 min at 37°C in a moist chamber, followed by
washes with 1 × PBS, 3 × 3 min. at RT. Slides were air dried
In vivo localisation of the canine HMGA1 protein Figure 4
In vivo localisation of the canine HMGA1 protein. In vivo localization of a canine HMGA1a-GFP fusion protein in culture 
canine MTH53A cells, 24 h posttranslational. a) GFP expression in canine mammary cell line MTH53A, b) DAPI fluorescent 
staining of cell nuclei, merged GFP and DAPI image, c) merged GFP and transmitted light image (magnification ×400).BMC Genetics 2008, 9:49 http://www.biomedcentral.com/1471-2156/9/49
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before chromosomes staining was performed with 25 μl
of Vectashield Mounting Medium with DAPI (Vector Lab-
oratories, Burlingame, CA, USA)
Ten well spread metaphases were examined indicating a
signal on CFA 12q11 on both chromatids of both chro-
mosomes CFA 12q11 (Fig. 1). The determination of chro-
mosomes follows the nomenclature of the canine
karyotype as described previously [26].
Genomic characterisation
For genomic characterisation of the canine HMGA1 gene
the missing parts were amplified by PCR on the screened
BAC clone MGA 572 P20 K12 RC. For the missing part 1
a 858 bp fragment (bankit 1078968) was generated with
primer pair A1_6640-6997_upa (5'-GGCGCGGCTCCAA-
GAA-3'), A1_6_lo_2 (5'-CCAACAGAGCCCTGCAAA-3'), a
1879 bp fragment (bankit 1078465 for the missing part 2
was generated by the primer pair A1_8864-10549_upa
(5'-GTCTCACCGTCTGGAGAAT-3'), A1_8864-10549_loa
(5'-TCACCGGAGGCTGCTT-3') and for the third missing
part a 979 bp fragment (bankit 1078536) was generated
with primer pair A1_11223-11834_upa (5'-
CTGAGCCCATGCCAGATAA-3'), A1_11223-11834_loa
(5'-AGAGATCCCTGCCGTAGT-3'). The obtained PCR
products were separated on a 1.5% agarose gel, recovered
with QIAquick Gel Extraction Kit (QIAGEN, Hilden, Ger-
many), cloned in pGEM-T Easy vector system (Promega,
Mannheim, Germany) and sequenced for verification.
The final genomic canine HMGA1 contig and the identity
alignments were created with Lasergene software (DNAS-
tar, Madison, USA) with the generated sequences from the
cloned cDNAs described previously and various
sequences from the NCBI database derived from the
canine genome sequencing (AY366394, AY366395,
AY366396, NM_001003387, NW_876254).
SNP screening
Genomic DNA was isolated from the collected 55 Dachs-
hunds samples using the QiaAmp kit (QIAGEN, Hilden,
Germany). A specific genomic PCR using the primer pair
A1In5up (5' GGCATCCGGTGAGCAGTG 3') and A1In6lo
(5' CAGGCAGAGCACGCAGGAC 3') was established
allowing the amplification of the complete exon 6 and
flanking regions of intron 5 and 6, respectively (Figure 3).
In detail the PCRs were performed in a 25 μl volume con-
taining 0.5 μM of both primers (MWG Biotech, Martin-
sried, Germany), 0.1 mM of each dNTP (Invitrogen,
Karlsruhe, Germany) 0.6 units Taq-DNA polymerase
(Promega, Mannheim, Germany), 1.5 mM MgCl2
(Promega, Mannheim, Germany), PCR buffer (Promega,
Mannheim, Germany) and 2.5 μl template DNA, contain-
ing averaged 26.5 ng/μl.
After an initial denaturation step of 5 min at 95°C, the
amplification followed in 30 cycles (30 sec. at 95°C, 30
sec at 59.3°C and 30 sec at 72°C). To complete, a final
elongation step for 10 min. at 72°C completed the proc-
ess. The obtained PCR products were purified using the
QIAquick PCR Purification Kit (Qiagen, Hilden, Ger-
many), directly sequenced by MWG Biotech (Martinsried,
Germany), and additionally digested enzymatically with
AluI (Fermentas, St. Leon-Rot, Germany). The occurrence
of the described SNP creates a new restriction site for the
enzyme AluI (5' AGtCT 3'). Thus, a digestion with AluI
cuts the 201 bp PCR product in two fragments of 69 bp
and 132 bp, respectively allowing a verification of the
sequencing results.
HMGA1 in vivo localisation
For the HMGA1 in vivo localisation the protein coding
sequence of the canine HMGA1a was amplified by PCR
using primer pair EcoR1_IY-upATG (5'-CGGAATTCCAC-
CATGAGCGAGTCGAGCTCGA-3'), BamH1_IY-loSTOP
(5'-CGGGATCCTCACTGCTCCTCTTCGGAGGACT-3').
The obtained PCR products were separated on a 1.5% aga-
rose gel, recovered with QIAquick Gel Extraction Kit (QIA-
GEN, Hilden, Germany), ligated into the pEGFP-C1
vector plasmid (BD Bioscience Clontech) and sequenced
for verification.
Cells from canine mammary tumour cell line MTH53a
were cultivated using medium 199 (Invitrogen, Karlsruhe,
Germany) supplemented with 20% FCS, penicillin, and
streptomycin. The transfection was performed according
to the manufacturer's instructions using 3 μl FugeneHD
reagent (Roche, Mannheim, Germany) in 100 μl PBS
(without Mg2+) containing 2 μg of recombinant pEGFP-
C1-HMGA1a. After treatment, the cells were incubated for
48 hours in the culture media. The uptake and expression
of DNA was verified by fluorescence microscopy.
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